Fresh analysis suggests that patients who stop using new slimming jabs like semaglutide or tirzepatide may regain shed pounds far faster than those who end traditional lifestyle regimens.
Research printed in a major health publication shows that while obese individuals can lose substantial amounts of their total mass while on the medication, the weight returns at an estimated rate of 0.8 kg per month upon discontinuation.
"Individuals purchasing these treatments should be cognizant of the danger of fast weight regain when the therapy is stopped," cautioned expert Dr. Susan Jebb.
Such speed of regain implies a return to starting weight within about one and a half years.
Weighing Therapies
The research, which looked at dozens of studies involving thousands of patients, contrasted the outcomes of the injectable medications with conventional dieting.
Researchers point out that individuals who lose weight through diet and exercise typically have a less rapid creep back—approximately 0.1 kg a month—once they finish.
Explaining the Quick Rebound
Doctors propose the mode of action of the injections explains the accelerated rebound.
These medications mimic a natural hormone called GLP-1, which moderates appetite.
"Long-term administration of the hormone levels far above than normal could lead to the system to generate a reduced amount of its endogenous GLP-1, and could reduce sensitivity to its effects," noted Dr. Adam Collins, a nutrition expert.
"Withdrawal of this medication leads to hunger is uncontrolled, making binge eating far more likely."
A Chronic Disease?
Health authorities suggest the jabs for individuals with obesity-related health risks, alongside prescribed diet and exercise modifications.
Professionals say that, given the likelihood of weight regain, the treatment should be considered ongoing.
This perspective is reinforced by drug manufacturers, who say that the findings "emphasize the persistent character of obesity," akin to managing conditions like high blood pressure.
Patient Testimonies
Users who have stopped the jabs explain a sudden return of cravings.
"It was like something flipping and you become extremely hungry," described an individual.
The struggle is exacerbated if users have not established permanent dietary or behavioural changes during treatment.
Growing Interest
Figures indicate that millions of adults in the UK have used weight-loss jabs in the last 12 months, with demand being substantial.
- Use is more common among women than men.
- The 40s and 50s age group shows the highest usage rates.
- A large proportion obtain the medications through private healthcare rather than the NHS.
In conclusion, clinicians caution that while GLP-1 drugs are potent agents for weight loss, they are not a magic cure and long-term success likely depends on combined lifestyle changes.
